Medtronic announced the treatment of the first patient in the United States in the Global SYMPLICITY Registry (GSR) DEFINE. The cl ...

Travere Therapeutics, Inc., today announced that the Company will present three abstracts on the effect of FILSPARI (sparsentan) in rare kidney disease at the upcoming International Podocyte ...

For patients with CKD and T2D, combination finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio than either agent alone.